Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00434044 | Study Evaluating Etanercept in the Treatment of Subjects With Ankylosing Spondylitis | PHASE3 | COMPLETED | 150 | — | — | Feb 1, 2007 | Jun 1, 2007 | Dec 13, 2007 | - | — |
| NCT00421915 | Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis | PHASE3 | COMPLETED | 84 | — | — | Mar 1, 2002 | Aug 1, 2002 | Jan 15, 2007 | - | — |
| Name | Type | Description |
|---|---|---|
| Enbrel (etanercept) | DRUG | - |
Inclusion Criteria: 1. Must be of Chinese ancestry and living in China. 2. Diagnosis of AS, as defined by Modified New York Criteria for Ankylosing Spondylitis. 3. Active AS at time of enrollment, defined by average of visual analog scale (VAS) values for duration and intensity of morning stiffness...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY002-072 |
| XBiotech, Inc. | XBIT | 1 | PHASE2 | vilamakitug |
| AbbVie, Inc. | ABBV | 1 | — | Upadacitinib |
| Pfizer Inc. | PFE | 1 | — | Tofacitinib |
| Novartis AG Sponsored ADR | NVS | 1 | — | Secukinumab |
| TScan Therapeutics, Inc. | TCRX | 1 | — | Undisclosed |